期刊文献+

氯沙坦对肾病综合征肾小管功能保护作用的临床研究 被引量:6

Protective effects of losartan on renal tubular of patients with nephrotic syndrome
下载PDF
导出
摘要 目的研究氯沙坦对肾病综合征肾小管功能的保护作用。方法 60例患者随机分为2组,治疗组给予强的松联合氯沙坦,对照组给予强的松。治疗12周后,观察两组血清白蛋白(sAlb)、24 h尿蛋白定量(24hup)、尿N-乙酰-β-D氨基葡萄糖苷酶(uNAG)、尿视黄醇结合蛋白(uRBP)、尿比重(SG)。结果经治疗,两组sAlb水平增高与治疗前比较,差异有统计学意义(P<0.05),24hup、uNAG、uRBP等指标降低与治疗前比较,差异有统计学意义(P<0.05),其中以治疗组24hup、uNAG、uRBP水平下降最为明显,与对照组比较,差异有统计学意义(P<0.05)。结论氯沙坦对肾病综合征肾小管功能具有保护作用。 Objective To study the effects of losartan on renal function of patients with nephrotic syndrome. Methods 60 patients were randomly divided into two groups,patients of treatment group were given prednisone and losartan,patients of control group received prednisone,after 12 weeks of treatment,the serum albumin(sAlb),24 h urinary protein(24hup),urinary N-acetyl-β-D-glucosaminidase(uNAG),urinary retinol-binding protein(uRBP),urine specific gravity(SG)were observed. Results After treatment,both groups' sAlb level increased(P0.05),24hup,uNAG,uRBP and other indicators decreased(P0.05),in which the decrease of 24hup,uNAG,uRBP of treatment group were more obvious than those of control group(P0.05). Conclusion Losartan has protective effect on renal function of patients with nephrotic syndrome.
出处 《实用药物与临床》 CAS 2011年第1期18-19,共2页 Practical Pharmacy and Clinical Remedies
关键词 肾小管 肾病综合征 氯沙坦 Tubular Nephrotic syndrome Losartan
  • 相关文献

参考文献7

二级参考文献25

  • 1林善锬.糖尿病肾病[J].中华内科杂志,2005,44(3):229-231. 被引量:117
  • 2中华人民共和国卫生部制定发布.中药新药研究指导原则(第1辑)[J].1993,:153-157. 被引量:1
  • 3Fujihara CK,Velho M,Malheiros DMAC,et al.An extremely high dose of losartan affords superior renoprotection in the remnant model[J].Kidney Int,2005,67 (5):1913-1924. 被引量:1
  • 4Brezniceanu ML,Wei CC,Zhang SL,et al.Tansforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells[J].Kidney Int,2006,69(11):1977-1985. 被引量:1
  • 5Huang Y,Wongamorntham S,Kasting J,et al.Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated angiotensin Ⅱ-independent mechanisms[J].Kidney Int,2006,69(1):105-113. 被引量:1
  • 6Suissa S,Hutchinson T,Brophy JM,et al.ACE -inhibitor use and the long-term risk of failure in diabetes[J].Kidney Int,2006,69(5):913 -919. 被引量:1
  • 7Katayama K,Nomura S,Ishikawa H,et al.Comparison between valsartan and valsartan plus cilnidipine in type Ⅱ diabetics with normo-and microalbuminuria[J].Kidney Int,2006,70 (1):151-156. 被引量:1
  • 8Franse LV , Pahor M, et al. Serum ufid. Diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) [J] .J Hypertens, 2000,18:1149 - 1154. 被引量:1
  • 9刘红.蛋白尿与慢性肾脏病变的进展[J].肾脏病与透析肾移植杂志,1997,6(4):357-362. 被引量:43
  • 10黄震华,徐济民.新型抗高血压药物氯沙坦[J].中国新药与临床杂志,1998,17(2):110-111. 被引量:30

共引文献42

同被引文献69

引证文献6

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部